Complement activation in IgA nephropathy
Complement activation in IgA nephropathy
IgA nephropathy pathogenesis is incompletely understood, and this limits the development of disease-specific biomarkers and effective therapies. Evidence of complement activity in IgA nephropathy is well established. However, a growing body of research indicates complement activity is an important contributor to IgA nephropathy pathology. In particular, multiple associations have been identified between complement alternative, lectin and terminal pathway proteins and IgA nephropathy severity. Recently, we have also gained insight into possible mechanisms that could link glomerular IgA deposition, complement activity, glomerular inflammation and disease severity. Ongoing clinical trials of therapeutic complement inhibitors will provide insight into the importance of complement activity to IgA nephropathy pathogenesis. Further research into mechanisms of complement activity is essential to improving our understanding and management of patients with IgA nephropathy.
Read abstract on library site Access full article
You may be interested in...
Developed by the Cystic Fibrosis Foundation, this position paper provides guidance on reproductive health care for individuals with cystic fibrosis. The recommendations address fertility, contraception, preconception counselling, pregnancy monitoring and the implications of CFTR modulator exposure during pregnancy and lactation.